Diagnosing the type of lung cancer from a tissue or liquid biopsy is absolutely critical to selecting treatment and determining the patient’s prognosis. However, for many lung cancer patients and their families, the role of tumor tissue in their diagnosis is a mystery. What happens to tissue collected in a biopsy? How is it analyzed? What is involved in getting helpful answers from biomarker testing? The specialized doctors responsible for answering these questions are pathologists. They identify any lung cancer cells in the biopsied tissue, and guide the patient’s biomarker testing. Unfortunately,… Read More
- #LCSM Chat Topic 05/09/2019: What’s new in early stage lung cancer
- #LCSM Chat Topic 04/11/2019: Why research matters for lung cancer
- #LCSM Chat Topic 03/07: Biomarker Magicians (or, Why We Love Pathologists)
- #LCSM Chat Topic 2019-02-07: Is it worth the drive?
- #LCSM Chat 2019/01/06–Immunotherapy: What Patients Need To Know
#LCAM14 ALK biomarker cancer treatment plans clinical research clinical trials Drugs EGFR epatients FDA immunotherapy LDCT lung cancer lung cancer awareness month lung cancer risk factors lung cancer screening Medicare coverage of LDCT over-treatment patient advocates PCORI Screening self-advocacy shared decision making trials World Cancer Day